If you've noticed persistent nausea, vomiting, or abdominal pain after starting Ozempic, you may be wondering whether these symptoms could signal gastroparesis. Decades of pharmacovigilance have shown that delayed gastric emptying can occur with GLP-1 receptor agonists, and recent case reports have sharpened the clinical picture. This page examines the published evidence and FDA labeling to help you understand who may need closer monitoring.
Building on the need for targeted pharmacovigilance, this article examines the specific relationship between Ozempic (semaglutide) and gastroparesis. Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its prescribing information documents a range of gastrointestinal adverse reactions, which are among the most common side effects reported in clinical trials. Gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction, is not explicitly listed as a labeled adverse reaction in the current prescribing information. However, the clinical presentation of gastroparesis—including nausea, vomiting, abdominal pain, and early satiety—overlaps significantly with the gastrointestinal symptoms reported in Ozempic-treated patients. Clinical trial data from the Ozempic prescribing information show that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo. In the pool of placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
The specific adverse reactions reported in ≥5% of Ozempic-treated patients with type 2 diabetes mellitus in placebo-controlled trials include nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms are consistent with the clinical presentation of gastroparesis, which typically includes nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal discomfort. Diagnosis of gastroparesis is confirmed through gastric emptying scintigraphy or other motility studies, but such diagnostic procedures are not routinely performed in clinical trials of Ozempic. Mechanistically, GLP-1 receptor agonists like semaglutide slow gastric emptying as part of their pharmacodynamic effect. This delay in gastric emptying is a known mechanism contributing to the glucose-lowering effects of these drugs, but it can also lead to symptoms of gastroparesis in susceptible individuals.
The prescribing information does not specifically list gastroparesis as a warning or precaution, but it does include pancreatitis, diabetic retinopathy complications, hypoglycemia with concomitant use of insulin secretagogues or insulin, acute kidney injury, hypersensitivity, and acute gallbladder disease as serious adverse reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific gastroparesis warning may leave patients and clinicians unaware of the potential for this condition to develop or worsen during treatment. Risk considerations for affected patients include the adequacy of current warnings. The prescribing information notes that gastrointestinal adverse reactions are common and often occur during dose escalation, but it does not explicitly address the possibility of gastroparesis. For patients who develop persistent or severe gastrointestinal symptoms, the differential diagnosis should include gastroparesis, particularly if symptoms do not resolve with dose adjustment or discontinuation. Causation-related considerations involve the temporal relationship between Ozempic exposure and symptom onset. In clinical trials, gastrointestinal symptoms typically emerged during dose escalation, suggesting a dose-dependent effect. However, the timeline for documented harm in individual cases may vary, and post-marketing reports could provide additional data on the latency between exposure and gastroparesis diagnosis. The available evidence from clinical trials indicates that gastrointestinal adverse reactions are dose-related and more common with higher doses of Ozempic. The overlap between these symptoms and gastroparesis highlights the need for clinicians to consider this condition in patients presenting with persistent nausea, vomiting, or abdominal pain while on Ozempic. Further research, including post-marketing surveillance and mechanistic studies, is warranted to clarify the incidence and risk factors for Ozempic-associated gastroparesis.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
The FDA has not issued a specific warning for gastroparesis in the Ozempic prescribing information. However, the label includes warnings for other serious adverse reactions such as pancreatitis and acute kidney injury. The absence of a gastroparesis warning may leave patients and clinicians unaware of the potential risk, despite the overlap between common gastrointestinal side effects and gastroparesis symptoms.
Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism of action. This delay in gastric emptying can lead to symptoms consistent with gastroparesis, such as nausea, vomiting, and abdominal pain. Clinical trials show dose-dependent gastrointestinal adverse reactions, with higher doses associated with increased incidence of these symptoms.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.